JB Chemicals & Pharmaceuticals’ (JBCPL) board has granted its approval to the company for entering into a definitive agreement to sell its Russia-CIS prescription products business to Dr Reddy’s Laboratories (DRL). The transaction which involves the sale of products registration, intellectual properties, etc is for the consideration worth Rs 137.5 crore.
However, the transaction which is conditional upon the customary closing condition including JBCPL‘s shareholder approval, is expected to close in the current quarter. Further, Bank of America is acting as exclusive financial advisor to the company.
Meanwhile, DRL’s affiliate has entered into contract with the company’s wholly owned subsidiary situated in Russia for the purchase of its inventory for a provisional consideration of $3.90 million. In addition to this, JBCPL has signed an agreement to supply DRL finished products for the acquired business.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: